The topical delivery of bromelain as an anti-inflammatory solution for skin inflammation has attracted the attention of researchers. Due to the skin barrier issue, a new method was designed for the effective delivery of specific doses of bromelain to the desired action sites. A niosome was selected as a novel and practical transdermal vehicle for the delivery of bromelain to inflamed sites. In this regard, a lipopolysaccharide (LPS)-induced human skin fibroblast (HSF1184) cell line was assembled in-vitro as a simulated model. The levels of interleukin-6 (IL-6) and tumour necrosisfactoralpha (TNF-α), the two immune-modulatory regulators of cell responses to inflammation were measured to determine the response towards the niosome-encapsulated bromelain treatment. The results showed that the niosome-encapsulated bromelain significantly reduced the levels of IL-6 and TNF-α compared to the non-encapsulated bromelain, the vehicle (niosome) and the control.
Niosome, human skin fibroblast, inflammation, IL-6, TNF-α, bromelain
Under Processing (Review Completed)
Editorial Information
Article Type
Research Article
Publication history
Received date: MAy 17, 2021
Accepted date: , 2021
Published date: 2021
Copyright
©2021 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation
(2021) Niosome Encapsulated Bromelain Reduced IL-6 and TNF-α in LPS Induced Human Skin Fibroblast Cell Line. OSP J Health Car Med 2: JHCM-2-128
Corresponding author
Siavash Hosseinpour Chermahini
Department of Bioprocess Engineering, Faculty of Chemical Engineering, Universiti Teknologi Malaysia, 81310 Johor Bahru, Johor, Malaysia.
s.chermahini@ug.edu.ge
